# Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C

Source: https://onco.cc/trials/nct05445778/  
OnCo record `nct05445778` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bevacizumab in ovarian cancer, run by AbbVie, active and no longer recruiting.

## Summary

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer is a phase 3 interventional study registered as NCT05445778 by AbbVie, with 520 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2027-04. Interventions recorded: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab. Conditions listed: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05445778
- Phase: 3
- Setting: Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
- Sponsor: AbbVie
- Enrolled: 520

## Sources

- ClinicalTrials.gov NCT05445778: https://clinicaltrials.gov/study/NCT05445778

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct05445778.json